The results of a pivotal multicenter, double-blind, randomized, placebo-controlled trial investigating the effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis were published on January 1, 2025. This publication provides insights into the study design and the findings regarding dapagliflozin's role in this chronic liver condition.
Background
Dapagliflozin is a medication that has been studied across various conditions. The trial specifically focused on metabolic dysfunction-associated steatohepatitis, a progressive chronic liver disease also known as MASH (Metabolic dysfunction-associated steatohepatitis) or formerly NASH (Non-alcoholic steatohepatitis). This condition is characterized by hepatic steatosis and inflammation, which can lead to fibrosis, cirrhosis, and liver failure. MASH represents a significant global health challenge with a growing prevalence and an urgent need for effective therapeutic interventions. This study aimed to evaluate the potential of dapagliflozin as a treatment option for this complex condition.
Trial design
The study, known as DEAN — Dapagliflozin Efficacy and Action in NASH, was designed as a rigorous multicentre, double-blind, randomised, placebo-controlled trial. This design is considered the gold standard for clinical research, ensuring a high level of evidence by minimizing bias. Participants were randomly assigned to receive either dapagliflozin or a placebo, with neither the participants nor the investigators knowing which treatment was administered. The trial's objective was to assess the effect of dapagliflozin on key parameters related to metabolic dysfunction-associated steatohepatitis.
What this means
The publication of the DEAN trial represents an important step in the ongoing effort to find effective treatments for metabolic dysfunction-associated steatohepatitis, also known as MASH. MASH is a condition with a substantial unmet medical need, and the exploration of existing medications like dapagliflozin in new indications is a common strategy to address such gaps. The robust design of this multicentre, double-blind, randomised, placebo-controlled trial suggests that the findings, once fully detailed, will contribute significantly to the understanding of dapagliflozin's potential in managing MASH. Clinicians and researchers will closely examine the full published data to evaluate the efficacy and safety profile of dapagliflozin for patients with this challenging liver disease, potentially guiding future treatment strategies.
Source
The information regarding this pivotal trial was published on January 1, 2025, in the BMJ, as referenced on PubMed. The article, titled "Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial," is available via PubMed at pubmed.ncbi.nlm.nih.gov.